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Summary
Background: Human herpes virus-7 (HHV-7) infection is widespread throughout the world. No
data are available in Argentina about loss of maternally-derived HHV-7 immunity and natural
infection.
Objectives: The objective of this study was to characterize the time when children lose maternal
antibodies and become susceptible to natural infection.
Methods: Sera from 39 pregnant women and 207 infants between 2 and 29 months of age were
tested. Determination of IgG antibodies was made by indirect immunofluorescence.
Results: The seropositive ratio fell in the 2—4 month group (15% seropositive) and increased
between 5 months (47% seropositive) and 23 months (67%). Geometric mean titers (GMT) of the
infants aged 2—4 months (GMT = 60) were statistically different ( p < 0.0001, Student’s t-test) to
those from the group of pregnant women (GMT = 83) and those from the other infant groups
(p < 0.001, least significant difference (LSD) test). The GMT of the groups between 5 and 23
months did not show significant differences whereas those of infants between 24 and 29 months
(GMT = 179, 79% seropositive) were different from all the groups studied ( p < 0.0001, LSD test).
Conclusions: This study shows a significant association between the loss of passive HHV-7
antibody and age. HHV-7 enters the susceptible population at 5 months, leading to the high
prevalence of antibodies between 24 and 29 months of age. This study also shows that natural
infection by HHV-7 in children during their first years of life follows the infection pattern found in
developing countries.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.§ Presented in part at the VIII Congreso Sociedad Argentina de Virologı´a Co´rdoba, Argentina, 2004.
* Corresponding author. Tel.: +54 351 4 33 20 23; fax: +54 351 4 33 20 23.
E-mail address: jpavan@mater.fcm.unc.edu.ar (J.V. Pavan).
1201-9712/$32.00 # 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2005.07.005
HHV-7 immunity in Argentinian infants 355
Table 1 HHV-7 antibodies in infants according to age group
Age
(months)
Number GMT of seropositive
children
Seropositive %
(95% CI)
2—4 26 60 15 (9—21)
5—8 27 110 47 (41—53)
9—11 48 102 43 (37—49)
12—15 28 83 53 (47—59)
16—19 26 102 65 (61—71)
20—23 28 96 67 (73—61)
24—29 24 179 79 (73—85)
GMT, geometric mean titers. CI, confidence interval.Introduction
The human herpesvirus-7 (HHV-7) is a lymphotropic virus that
was first isolated in 1990 from T-lymphocytes in peripheral
blood and saliva of healthy subjects.1 The isolation of HHV-7
raises questions regarding its prevalence in humans and its
potential association with disease. This virus has been asso-
ciated with exanthem subitum, infectious mononucleosis,
and chronic fatigue syndrome among others, even when its
specific pathogenic role remains unclear.2 Primary infection
usually occurs in early childhood, often without symptoms,
and subsequently the virus persists in the host and is shed in
saliva throughout life.3
HHV-7, since its isolation, has been found to be closely
related to the human herpesvirus-6 (HHV-6) and shares some
common antigenic epitopes. Different strategies have been
applied to detect anti-HHV-7 antibodies.4 The immunofluor-
escence assay for detecting IgG has demonstrated sensitivity
and specificity to detect specific antibodies with little cross-
reactivity towards HHV-6.5,6
Recent studies indicate ubiquity of HHV-7 in most of the
populations studied. However, there is little information
about the circulation of this virus in developing countries.
In Argentina no data are available about infection by HHV-7
and the natural history of the infection remains unknown.
This article aims to provide evidence about the loss of
maternally-derived immunity and HHV-7 natural infection
in Argentinian infants, identifying its particular character-
istics.
Materials and methods
Population study
Co´rdoba is the capital city of the Province of Co´rdoba with a
population of 2 750 000 inhabitants. Sera from 207 healthy
infants (aged between 2 and 29 months) and 39 pregnant
women collected during routine checkups during the period
1995—96 in the Children’s Hospital and in the General Direc-
tion of Medical Specialities in Co´rdoba City were used to
investigate the duration of transplacentally-derived HHV-7
immunity. A written consent was obtained from the parents
of the children. All infants were born after 36 weeks of
gestation weighing >2500 g.
Serologic evaluation
An indirect immunofluorescence assay (IFA) was carried out
using multi-well Teflon-coated slides prepared with the lym-
phoid cell line Supt 1, infected with the SB HHV-7 viral strain.
It has previously been determined that the optimal post-
infection culture day to be used as a source of viral antigen
was day 10 post-infection (data not shown). IFA staining was
performed by the standard procedure used in our laboratory.
Briefly, 10-fold dilutions of serum samples were incubated
with fixed cells for 30 min at 37 8C in a humidified chamber,
washed twice with phosphate buffered saline (PBS) for 5 min
and incubated for 30 min at 37 8C with fluorescein isothio-
cyanate-conjugated goat antihuman IgG serum. The slides
were mounted with glycerol buffer on coverslips and then
examined under a fluorescent microscope.The highest serum dilution that exhibited a specific fluor-
escence pattern was considered the endpoint of antibody
titration. Titers 1:60 were considered significant.
Data analysis
Geometric mean titers (GMT) were calculated only for indi-
viduals with detectable antibodies in the following way: the
reciprocals of HHV-7 antibody titers were logarithmically
converted and the antilogarithmwas calculated. To calculate
the size of the sample, the prevalence of anti-HHV-7 anti-
bodies was considered to be 70% according to published
data,4 with a confidence level of 95%.7
The statistical methodologies were: (a) the Student’s t-
test, to compare the mean of independent samples and (b)
the analysis of variance (ANOVA) with one main explanatory
variable. The post mean comparison test was later applied
using the least significant difference (LSD) test.
Results
The results from maternally-derived HHV-7 antibody titers by
age group are summarized in Table 1. The mean ratio of
seropositive pregnant women was 48% with a GMT of 83.
The seropositive ratio dropped in the 2—4 month group (15%
seropositive) and rose between 5 months (47% seropositive)
and 23 months (67%). The GMT in infants from 2 to 4 months
showed statistically significant differences with the group of
pregnant women (p < 0.0001, Student’s t-test). Significant
differences were also found in the GMT of the other infant
groups (ANOVA, p < 0.0001). The group aged between 2 and 4
months was significantly different from all the other groups:
with the group aged between 5 and 8 months (p < 0.001, LSD
test), with the groups aged between 9 and 15 months
(p < 0.002, LSD test), and with the groups aged between 16
and 29 months (p < 0.0001, LSD test). The groups between 5
and23months didnot showsignificant differences. The infants
aged 24 to 29 months had a GMTof 179 and 79% seropositivity.
This group was significantly different from all the other groups
of infants (p < 0.0001, LSD test) (Figure 1).
Discussion
Seroprevalence of antibodies in pregnant women would
indirectly reflect HHV-7 seroprevalence in their infants in
early life. Passive immunity protects infants from infection
by HHV-7 during the first months of life.
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Figure 1 Prevalence of HHV-7 antibodies and the geometric mean titers of HHV-7 detectable antibodies in infants by age group: (1)
2—4 months, (2) 5—8 months, (3) 9—11 months, (4) 12—15 months, (5) 16—19 months, (6) 20—23 months, and (7) 24—29 months.The diminution of the GMT in infants aged 2 to 4 months
with respect to the values in pregnant women would derive
from the catabolism of maternal IgG. Although there has
been no direct proof of protection by maternal HHV-7 anti-
bodies, this study shows that HHV-7 infection increases after
the fifth month of life, suggesting a protective role for the
maternal antibody during the first four months of life. If so,
the prevalence and antibody titers observed in 2 to 4 month-
old infants would be as a result of transplacental antibodies
and/or antibodies resulting from primary infection.
HHV-7 primary infection took place around 5—8 months of
age, and the immune system received a boost at a later time,
around 2 years of age.
In a previous report we have demonstrated that HHV-6
enters into the susceptible population between 13 and 15
months of age.8 In the present report the results are surpris-
ing as primary infection with HHV-7 occurs earlier than with
HHV-6. The explanation is very unlikely to lie in antibody
cross-reactivity between HHV-7 and HHV-6 as measured by
immunofluorescence tests. The limited cross-reactivity
between naturally induced human antibodies against the
two viruses has been taken into account. According to several
researchers,2,9 in the sera with low IgG titers for HHV-7
(1:30), a cross-reactivity with HHV-6 is probable. For this
reason in our study the serum starting at dilution 1:60 was
considered significant.
In order to determine the age of primary acquisition ofHHV-
7, we referred to Oliveira et al.,10 who have reported 71% of
HHV-7 primary infection in children less than 1 year old in a
tropical region of Brazil. The onset of HHV-7 antibodies within
the first year has also been reported in Hungarian children.11
On the other hand, according to some authors,2,9,12 HHV-7
infection usually occurs later, being gradually acquired over
the first five or six years of life with about 65% of children
infected by the age of three. Furthermore, Yoshikawa et al.13
have reported that in Japan, the children reached the highest
level (60%) at 11—13 years of age.Onaccount of thesefindings,
it seems probable that epidemiology of HHV-7 could have two
different patterns, one of early primary infection in thedeveloping world and another one of late primary infection
in the industrial or developed nations.
This study shows that natural infection by HHV-7 in chil-
dren during their first years of life follows the infection
pattern found in the developing countries. This constitutes
a starting point in the examination of the pathogenic role of
this virus in different clinical entities.
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